Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor

Abstract

This study demonstrates the development of an in vitro model of acquired resistance to targeted therapy in canine MCTs harboring a c-kit-activating mutation. This model may be used to investigate the molecular basis of and strategies to overcome TOC resistance.